Kuhn W - Search Results

1

Genetic analysis of immunomodulating factors in sporadic Parkinson's disease.

Krüger R, Hardt C, Tschentscher F, Jäckel S, Kuhn W, Müller T, Werner J, Woitalla D, Berg D, Kühnl N, Fuchs GA, Santos EJ, Przuntek H, Epplen JT, Schöls L, Riess O. Krüger R, et al. Among authors: kuhn w. J Neural Transm (Vienna). 2000;107(5):553-62. doi: 10.1007/s007020070078. J Neural Transm (Vienna). 2000. PMID: 11072751

2

Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease.

Heinz A, Suchy I, Klewin I, Kuhn W, Klotz P, Przuntek H. Heinz A, et al. Among authors: kuhn w. J Neural Transm Park Dis Dement Sect. 1992;4:291-301. doi: 10.1007/BF02260078. J Neural Transm Park Dis Dement Sect. 1992. PMID: 1388700

3

Continuous subcutaneous lisuride infusion in OPCA.

Heinz A, Wöhrle J, Schöls L, Klotz P, Kuhn W, Przuntek H. Heinz A, et al. Among authors: kuhn w. J Neural Transm Gen Sect. 1992;90(2):145-50. doi: 10.1007/BF01250796. J Neural Transm Gen Sect. 1992. PMID: 1463593

4

The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.

Przuntek H, Kuhn W. Przuntek H, et al. Among authors: kuhn w. Adv Neurol. 1990;53:445-9. Adv Neurol. 1990. PMID: 1700583 No abstract available.

5

(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.

Russ H, Gerlach M, Dettner O, Kuhn W, Przuntek H. Russ H, et al. Among authors: kuhn w. J Neural Transm Park Dis Dement Sect. 1991;3(3):215-23. doi: 10.1007/BF02259539. J Neural Transm Park Dis Dement Sect. 1991. PMID: 1958292

6

Urinary dopamine sulfate: regulations and significance in neurological disorders.

Kienzl E, Eichinger K, Sofic E, Jellinger K, Riederer P, Kuhn W, Fuchs G, Laux G. Kienzl E, et al. Among authors: kuhn w. J Neural Transm Suppl. 1990;32:471-9. doi: 10.1007/978-3-7091-9113-2_64. J Neural Transm Suppl. 1990. PMID: 2089110

7

Comparison of two methods for the determination of substance P immunoreactivity in human cerebrospinal fluid: sulphopropyl-Sephadex ion-exchange chromatography and/or reversed-phase high-performance liquid chromatography combined with radioimmunoassay.

Wallasch TM, Henning K, Lange U, Kuhn W, Eckhardt-Wallasch H, Przuntek H. Wallasch TM, et al. Among authors: kuhn w. J Chromatogr. 1988 Mar 4;425(1):175-81. doi: 10.1016/0378-4347(88)80018-5. J Chromatogr. 1988. PMID: 2452174 No abstract available.

8

The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.

Przuntek H, Kuhn W, Kraus P. Przuntek H, et al. Among authors: kuhn w. Acta Neurol Scand Suppl. 1989;126:153-6. doi: 10.1111/j.1600-0404.1989.tb01795.x. Acta Neurol Scand Suppl. 1989. PMID: 2482649

9

The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.

Przuntek H, Kuhn W. Przuntek H, et al. Among authors: kuhn w. J Neural Transm Suppl. 1987;25:97-104. J Neural Transm Suppl. 1987. PMID: 3123607 Clinical Trial.

10

Pharmacokinetic studies with sustained-release formulations of levodopa in healthy volunteers.

Gerlach M, Gebhardt B, Kuhn W, Przuntek H. Gerlach M, et al. Among authors: kuhn w. J Neural Transm Suppl. 1988;27:211-8. doi: 10.1007/978-3-7091-8954-2_18. J Neural Transm Suppl. 1988. PMID: 3165436 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

929 results

Search Page

Filters